|
|
非酒精性脂肪性肝病发病机制及治疗方案研究进展
|
Abstract:
非酒精性脂肪性肝病(NAFLD)包括广泛的病理，从非酒精性脂肪肝(NAFL)，其特征是没有炎症的简单脂肪变性，到非酒精性脂肪性肝炎(NASH)，其特征是肝脏脂肪变性伴有炎症和肝细胞气球形成，可导致晚期纤维化，肝硬化和肝细胞癌。饮食和生活方式的改变被认为是非药物治疗策略；然而，由于NAFLD发病机制复杂，目前的药物治疗主要以致病因素、发病机制的关键环节以及相关的代谢紊乱为靶点。仍然缺乏特定的药物。在临床研究中，常见的NAFLD治疗包括调节葡萄糖和脂质代谢以保护肝脏和抗炎。基于肝肠轴、靶向肠道菌群的NAFLD治疗正在逐步涌现，各种新的代谢调节药物也在临床开发中。因此，本文综述了近年来NAFLD治疗的研究进展。
Nonalcoholic fatty liver disease (NAFLD) encompasses a wide range of pathologies, from nonalcoholic fatty liver disease (NAFL), which is characterized by simple steatosis without inflammation, to nonalcoholic steatohepatitis (NASH), which is characterized by hepatic steatosis with inflammation and hepatocyte balloon formation, which can lead to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Dietary and lifestyle changes are considered nonpharmacological treatment strategies; however, due to the complex pathogenesis of NAFLD, current drug treatments mainly target pathogenic factors, key links in the pathogenesis, and related metabolic disorders. There is still a lack of specific medications. In clinical studies, common NAFLD treatments include modulation of glucose and lipid metabolism to protect the liver and anti-inflammatory. NAFLD treatments based on the hepatoenteropathic axis and targeting the intestinal microbiota are gradually emerging, and various new metabolic modulation drugs are also in clinical development. Therefore, this article reviews the research progress in the treatment of NAFLD in recent years.
| [1] | Tilg, H., Adolph, T.E., Dudek, M., et al. (2021) Non-Alcoholic Fatty Liver Disease: The Interplay between Metabolism, Microbes and Immunity. Nature Metabolism, 3, 1596-1607. https://doi.org/10.1038/s42255-021-00501-9 |
| [2] | Henao-Mejia, J., Elinav, E., Jin, C., et al. (2012) Inflammasome-Mediated Dysbiosis Regulates Progression of NAFLD and Obesity. Nature, 482, 179-185. https://doi.org/10.1038/nature10809 |
| [3] | Tilg, H. and Effenberger, M. (2020) From NAFLD to MAFLD: When Pathophysiology Succeeds. Nature Reviews Gastroenterology & Hepatology, 17, 387-388. https://doi.org/10.1038/s41575-020-0316-6 |
| [4] | Wang, X., Zheng, Z., Caviglia, J.M., et al. (2016) Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 24, 848-862. https://doi.org/10.1016/j.cmet.2016.09.016 |
| [5] | Mahlapuu, M., Caputo, M., Xia, Y., et al. (2022) GCKIII Kinases in Lipotoxicity: Roles in NAFLD and Beyond. Hepatology Communications, 6, 2613-2622. https://doi.org/10.1002/hep4.2013 |
| [6] | Herman, M.A. and Samuel, V.T. (2016) The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis. Trends in Endocrinology & Metabolism, 27, 719-730. https://doi.org/10.1016/j.tem.2016.06.005 |
| [7] | Porto, A., Pan, Z., Zhou, W., et al. (2022) Macronutrient and Micronutrient Intake in Adolescents with Non-Alcoholic Fatty Liver Disease: The Association with Disease Severity. Journal of Pediatric Gastroenterology and Nutrition, 75, 666-674. https://doi.org/10.1097/MPG.0000000000003578 |
| [8] | De Munck, T., Xu, P., Verwijs, H., et al. (2020) Intestinal Permeability in Human Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Liver International, 40, 2906-2916. https://doi.org/10.1111/liv.14696 |
| [9] | Fang, J., Yu, C.H., Li, X.J., et al. (2022) Gut Dysbiosis in Nonalcoholic Fatty Liver Disease: Pathogenesis, Diagnosis, and Therapeutic Implications. Frontiers in Cellular and Infection Microbiology, 12, Article 997018. https://doi.org/10.3389/fcimb.2022.997018 |
| [10] | Cai, D., Yuan, M., Frantz, D.F., et al. (2005) Local and Systemic Insulin Resistance Resulting from Hepatic Activation of IKK-Beta and NF-KappaB. Nature Medicine, 11, 183-190. https://doi.org/10.1038/nm1166 |
| [11] | Huh, J.Y. and Saltiel, A.R. (2021) Roles of IκB Kinases and TANK-Binding Kinase 1 in Hepatic Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Experimental & Molecular Medicine, 53, 1697-1705. https://doi.org/10.1038/s12276-021-00712-w |
| [12] | Duan, Y., Pan, X., Luo, J., et al. (2022) Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 13, Article 880298. https://doi.org/10.3389/fimmu.2022.880298 |
| [13] | Risi, R., Tozzi, R. and Watanabe, M. (2021) Beyond Weight Loss in Nonalcoholic Fatty Liver Disease: The Role of Carbohydrate Restriction. Current Opinion in Clinical Nutrition & Metabolic Care, 24, 349-353. https://doi.org/10.1097/MCO.0000000000000762 |
| [14] | Wong, V.W., Wong, G.L., Chan, R.S., et al. (2018) Beneficial Effects of Lifestyle Intervention in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 69, 1349-1356. https://doi.org/10.1016/j.jhep.2018.08.011 |
| [15] | Estes, C., Anstee, Q.M., Arias-Loste, M.T., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. https://doi.org/10.1016/j.jhep.2018.05.036 |
| [16] | Ali, A., Amin, M.J., Ahmed, M.U., et al. (2022) Frequency of Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Associated Risk Factors among Type-2 Diabetics. Pakistan Journal of Medical Sciences, 38, 28-33. https://doi.org/10.12669/pjms.38.1.4968 |
| [17] | Petit, J.M. and Vergès, B. (2017) Glp-1 Receptor Agonists in NAFLD. Diabetes & Metabolism, 43, 2S28-2S33. https://doi.org/10.1016/S1262-3636(17)30070-8 |
| [18] | Colosimo, S., Ravaioli, F., Petroni, M.L., et al. (2021) Effects of Antidiabetic Agents on Steatosis and Fibrosis Biomarkers in Type 2 Diabetes: A Real-World Data Analysis. Liver International, 41, 731-742. https://doi.org/10.1111/liv.14799 |
| [19] | Zhang, Q.Q. and Lu, L.G. (2015) Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. Journal of Clinical and Translational Hepatology, 3, 78-84. https://doi.org/10.14218/JCTH.2014.00037 |
| [20] | Van Der Graaff, D., Chotkoe, S., De Winter, B., et al. (2021) Vasoconstrictor Antagonism Improves Functional and Structural Vascular Alterations and Liver Damage in Rats with Early NAFLD. JHEP Reports, 4, Article 100412. https://doi.org/10.1016/j.jhepr.2021.100412 |
| [21] | Nadinskaia, M., Maevskaya, M., Ivashkin, V., et al. (2021) Ursodeoxycholic Acid as a Means of Preventing Atherosclerosis, Steatosis and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. World Journal of Gastroenterology, 27, 959-975. https://doi.org/10.3748/wjg.v27.i10.959 |
| [22] | Aron-Wisnewsky, J., Warmbrunn, M.V., Nieuwdorp, M., et al. (2020) Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology, 158, 1881-1898. https://pubmed.ncbi.nlm.nih.gov/32044317/ https://doi.org/10.1053/j.gastro.2020.01.049 |
| [23] | Siddiqui, M.S., Idowu, M.O., Parmar, D., et al. (2021) A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 19, 2670-2672. https://doi.org/10.1016/j.cgh.2020.10.051 |
| [24] | Harrison, S.A., Bashir, M.R., Guy, C.D., et al. (2019) Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet, 394, 2012-2024. https://doi.org/10.1016/S0140-6736(19)32517-6 |
| [25] | Talukdar, S. and Kharitonenkov, A. (2021) FGF19 and FGF21: In NASH We Trust. Molecular Metabolism, 46, Article 101152. https://doi.org/10.1016/j.molmet.2020.101152 |
| [26] | Harrison, S.A., Neff, G., Guy, C.D., et al. (2021) Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology, 160, 219-231. https://doi.org/10.1053/j.gastro.2020.08.004 |
| [27] | Safadi, R., Braun, M., Francis, A., et al. (2021) Randomised Clinical Trial: A Phase 2 Double-Blind Study of Namodenoson in Non-Alcoholic Fatty Liver Disease and Steatohepatitis. Alimentary Pharmacology & Therapeutics, 54, 1405-1415. https://doi.org/10.1111/apt.16664 |
